Arcus Biosciences Price to Sales Ratio 2017-2023 | RCUS
Historical PS ratio values for Arcus Biosciences (RCUS) over the last 10 years. The current P/S ratio for Arcus Biosciences as of June 05, 2023 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Arcus Biosciences P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2023-06-05 |
20.54 |
|
12.47 |
| 2023-03-31 |
18.24 |
$1.65 |
11.07 |
| 2022-12-31 |
20.68 |
$1.56 |
13.28 |
| 2022-09-30 |
26.16 |
$5.88 |
4.45 |
| 2022-06-30 |
25.34 |
$5.55 |
4.56 |
| 2022-03-31 |
31.56 |
$5.32 |
5.94 |
| 2021-12-31 |
40.47 |
$5.20 |
7.78 |
| 2021-09-30 |
34.87 |
$0.59 |
58.75 |
| 2021-06-30 |
27.46 |
$1.45 |
18.95 |
| 2021-03-31 |
28.08 |
$1.35 |
20.81 |
| 2020-12-31 |
25.96 |
$1.25 |
20.80 |
| 2020-09-30 |
17.14 |
$1.29 |
13.30 |
| 2020-06-30 |
24.74 |
$0.34 |
73.23 |
| 2020-03-31 |
13.88 |
$0.34 |
40.61 |
| 2019-12-31 |
10.10 |
$0.34 |
29.49 |
| 2019-09-30 |
9.10 |
$0.17 |
55.11 |
| 2019-06-30 |
7.95 |
$0.23 |
35.26 |
| 2019-03-31 |
12.49 |
$0.21 |
58.12 |
| 2018-12-31 |
10.77 |
$0.31 |
35.15 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.536B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
